At 9.1% CAGR, North America Custom Antibody Services Market is Projected to be Worth US$ 577.76 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the North America custom antibody services market was valued at US$ 287.49 million in 2023 and is expected to reach US$ 577.76 million by 2031, registering a CAGR of 9.1% from 2023 to 2031. Increasing prevalence of chronic diseases and rising approvals of biosimilars are among the critical factors attributed to the North America custom antibody services market expansion.

The increasing aging population, changing social behavior, and rising adoption of a sedentary lifestyle by people, along with accelerating urbanization, boost the prevalence of obesity and various chronic diseases. Also, twin studies have established that genes can cause chronic conditions such as cardiovascular disease (CVDs), diabetes, obesity, Alzheimer's disease (AD), and depression. According to the National Council on Aging, Inc., 80% of adults aged 65 and above have at least one chronic condition, while 68% have two or more. As per The Centers for Disease Control and Prevention (CDC), in 2020, almost 6 in 10 people in the US suffered from at least one chronic disease, and 4 in 10 people had two or more chronic conditions.

Cardiovascular diseases such as atherosclerosis, angina pectoris, and acute myocardial infarction, caused due to hectic lifestyles, are significant causes of mortality across the globe. As per the data provided by the WHO, CVDs are the leading cause of death worldwide, recording ~17.9 million deaths each year. Diabetes is a life-threatening chronic disease with no functional cure. Diabetes of all types can lead to various complications in the body and increase the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are among the major complications associated with diabetes. According to the International Diabetes Federation (IDF), diabetic cases in North America are expected to reach 62 million by 2045 from 46 million in 2017. Furthermore, 425 million people were suffering from diabetes in 2017, and the figure is expected to reach 629 million by 2045 worldwide; this is likely to boost the disease prevalence by ~35% during the forecast period.

Recognition of biosimilars and monoclonal antibodies as efficacious and safe agents by patients, specialists, primary care clinicians, and other healthcare professionals is propelling the demand for biosimilars. In addition, biosimilars help improve the quality of life for millions of patients while saving costs for the healthcare system per year. They are effective and cost-effective options in treating many diseases, including chronic skin conditions and bowel diseases, such as Crohn's disease, psoriasis, irritable bowel syndrome, and colitis; diabetes; autoimmune disease; cancer; kidney conditions; and arthritis.

As the prevalence of chronic diseases is increasing at a high rate, the demand for custom antibodies to treat life-threatening illnesses has progressed rapidly over the past few years, which drives the custom antibody services market.

On the contrary, high costs and complexities associated with antibody production using transgenic animals hamper the growth of North America custom antibody services market.

Based on product type, the North America custom antibody services market is segmented into monoclonal, polyclonal hybridoma, recombinant antibody, and others. The monoclonal segment held 50.2% share of the North America custom antibody services market in 2023, amassing US$ 144.45 million. It is projected to garner US$ 283.40 million by 2031 to expand at 8.8% CAGR during 2023-2031.

Based on service type, the North America custom antibody services market is segmented into antibody discovery and development, antibody production services, and others. The antibody discovery and development segment held 60.2% share of the North America custom antibody services market in 2023, amassing US$ 173.10 million. It is projected to garner US$ 352.03 million by 2031 to expand at 9.3% CAGR during 2023-2031.

Based on application, the North America custom antibody services market is segmented into immunohistochemistry, western blot & IP, ELISA, fluorescence-activated cell sorting, mass spectrometry, and others. The ELISA segment held 40.9% share of the North America custom antibody services market in 2023, amassing US$ 117.67 million. It is projected to garner US$ 231.38 million by 2031 to expand at 8.8% CAGR during 2023-2031.

Based on disease indication, the North America custom antibody services market is segmented into oncology, infectious diseases, immunology, cardiovascular diseases, and others. The oncology segment held 45.4% share of the North America custom antibody services market in 2023, amassing US$ 130.46 million. It is projected to garner US$ 269.54 million by 2031 to expand at 9.5% CAGR during 2023-2031.

Based on source, the North America custom antibody services market is segmented into chicken, rabbits, rats, guinea pigs, mouse or humanized mice, and others. The mouse or humanized mice segment held 39.9% share of the North America custom antibody services market in 2023, amassing US$ 114.66 million. It is projected to garner US$ 224.45 million by 2031 to expand at 8.8% CAGR during 2023-2031. The mouse or humanized mice segment is further sub segmented into monoclonal antibody platform, BsAB discovery platform, bispecific ADC platform, TCR-mimic antibody platform, Anti-GPCR antibody technology platform, and others.

Based on end user, the North America custom antibody services market is segmented into life science industry, pharmaceutical & biotech companies, academic & research institutes, and contract research organizations. The life science industry segment held 35.3% share of the North America custom antibody services market in 2023, amassing US$ 101.47 million. It is projected to garner US$ 197.02 million by 2031 to expand at 8.6% CAGR during 2023-2031.

Based on country, the North America custom antibody services market is segmented into the US, Canada, and Mexico. The US held 85.1% share of North America custom antibody services market in 2023, amassing US$ 244.65 million. It is projected to garner US$ 496.76 million by 2031 to expand at 9.3% CAGR during 2023-2031.

Key players operating in the custom antibody services market are Thermo Fisher Scientific Inc; Sino Biological Inc.; GenScript Biotech Corporation; Biochain Incorporated; R&D Systems, Inc; Kaneka Eurogentec S.A.; Fortis Life Sciences; Precision Antibody (A&G Pharmaceutical, Inc.; Biocytogen Pharmaceuticals Beijing Co Ltd; Abgenex; Creative Biolabs Inc; Agilent Technologies Inc; Bioklone; and Scantibodies Laboratory, Inc., among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com